ArticleBMJ open2024

Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.

Hongfu Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.